Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights
A Phase 2 clinical study with PL9643 for dry eye disease started in January 2020, and active patients continue treatment and monthly clinic visits.
- A Phase 2 clinical study with PL9643 for dry eye disease started in January 2020, and active patients continue treatment and monthly clinic visits.
- Data readout is targeted for the fourth quarter of calendar year 2020.
- Totaloperating expenses for the quarter ended March 31, 2020 were $5.7 million compared to $5.8 million for the comparable quarter of 2019.
- The difference in financial results between the three months ended March 31, 2020 and 2019 was mainly attributable to the increase in other income, net.